Trait Biosciences reports early CBD82S pet mobility findings

Trait Biosciences says a 14-day in-home evaluation of its water-soluble CBD ingredient showed owner-reported changes in mobility-related behavior in companion animals with joint discomfort. The company says the findings support its push to make cannabinoids easier to formulate and deliver across animal health products. Why it matters: - Trait Biosciences is trying to solve a core cannabinoid formulation problem: CBD’s poor water solubility. - Better solubility can affect bioavailability, dosing consistency, stability and the kinds of products developers can make for animal health. - The pet study adds an early real-world use case for CBD82S™, the company’s lead water-soluble cannabidiol ingredient. What happened: - Trait Biosciences announced exploratory observational findings from a 14-day in-home evaluation of CBD82S™ in companion animals. - The animals had owner-reported joint discomfort and mobility limitations. - The product was applied topically once a day, with dosing adjusted for body weight. - Owners reported changes over the evaluation period in walking, standing and jumping. - Owners also reported changes in activity levels, engagement, comfort-related behavior and demeanor. The details: - The company says cannabidiol has been studied for possible roles in inflammation-related pathways and mobility-related outcomes in animal health. - Trait Biosciences says conventional cannabinoids face formulation limits because CBD does not dissolve well in water. - The company says its technology converts hemp-derived cannabinoids into water-soluble forms through multiple processes. - Trait Biosciences says those processes produce highly purified CBD designed to address aqueous solubility, formulation stability, dosing consistency and compatibility with different delivery formats. - The company says improved molecular-level solubility expands formulation options for cannabinoid-infused products in animal health and other bioactive delivery applications. - CBD82S™ is the first of multiple cannabinoid molecules in development within Trait Biosciences’ broader platform pipeline. - Dr. Hanny Kanafani, president and COO of Trait Biosciences, said the company is focused on applying biochemical and formulation science to the solubility limits of cannabinoids. - Kanafani said the company’s technology is designed to improve CBD performance characteristics such as consistency and absorption potential across delivery formats. Between the lines: - The findings are exploratory and observational, not a controlled efficacy study. - Owner-reported behavior changes can be useful for early signal detection, but they do not establish clinical proof on their own. - Trait Biosciences is positioning itself less as a consumer brand and more as a B2B ingredients company for animal health, nutraceutical and other bioactive formulations. What’s next: - Trait Biosciences says it will continue developing additional cannabinoid molecules within its platform pipeline. - The company is also seeking collaboration opportunities with developers working in animal health and related formulation areas. - More information is available in the company’s announcement: the company’s announcement - The company also links to its video channel: Trait Biosciences on YouTube The bottom line: - Trait Biosciences is betting that water-soluble cannabinoid science can make CBD easier to formulate and potentially more useful in companion-animal products.